Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Eton Pharmaceuticals, Inc. (ETON) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results"
07/05/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Eton Pharmaceuticals Reports First Quarter 2023 Financial Results ● Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 ● Launched Betaine Anhydrous"
05/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution — Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients*"
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/20/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results"
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 — Product is targeting a rare pediatric endocrinology condition — — Potential for NDA submission in Q2 2024"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/08/2023 3 Krempa David (Chief Business Officer) has filed a Form 3 on Eton Pharmaceuticals, Inc.
03/01/2023 8-K Quarterly results
01/20/2023 SC 13G/A Opaleye Management Inc. reports a 8.6% stake in ETON PHARMACEUTICALS, INC.
01/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection — Product previously granted orphan drug designation for methanol poisoning — — Application assigned a PDUFA date of June 27, 2023"
12/28/2022 8-K Other Events  Interactive Data
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
09/23/2022 4 BRYNJELSEN SEAN (CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns: Bought 10,000 shares @ $2.1042, valued at $21k
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution -- Expected to be accretive to 2023 earnings --"
08/12/2022 8-K Other Events  Interactive Data
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
07/18/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy